A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.
about
Systematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reactionEffectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed ViremiaComparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trialPredictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or abacavir-lamivudineEvaluation of cardiovascular biomarkers in HIV-infected patients switching to abacavir or tenofovir based therapy.Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use.Safety analysis of Ziagen® (abacavir sulfate) in postmarketing surveillance in JapanLipid Metabolism and Cardiovascular Risk in HIV-1 Infection and HAART: Present and Future Problems.HIV and HAART-Associated DyslipidemiaAntiretroviral therapy for adults infected with HIV: Guidelines for health care professionals from the Quebec HIV care committeeProtease Inhibitors and Renal Function in Patients with HIV Infection: a Systematic Review.Abacavir/lamivudine fixed-dose combination antiretroviral therapy for the treatment of HIV.Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.Comparative effectiveness of tenofovir in HIV-infected treatment-experienced patients: systematic review and meta-analysis.Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients.Abacavir/lamivudine versus tenofovir/emtricitabine in virologically suppressed patients switching from ritonavir-boosted protease inhibitors to raltegravir.Association of tenofovir exposure with kidney disease risk in HIV infection.Exploratory Analysis for the Evaluation of Estimated Glomerular Filtration Rate, Cholesterol and Triglycerides after Switching from Tenofovir/Emtricitabine plus Atazanavir/Ritonavir (ATV/r) to Abacavir/Lamivudine plus ATV/r in Patients with PreserveComparative efficacy of Lamivudine and emtricitabine: a systematic review and meta-analysis of randomized trialsLower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials.Bone mineral density in HIV-infected women taking antiretroviral therapy: a systematic review.From old to new nucleoside reverse transcriptase inhibitors: changes in body fat composition, metabolic parameters and mitochondrial toxicity after the switch from thymidine analogs to tenofovir or abacavir.Renal toxicity associated with antiretroviral therapy.When can HIV clinical trials detect treatment effects on drug resistance?Switch strategies in antiretroviral therapy regimens.Switching antiretroviral regimes for the treatment of HIV: safety implications.NRTI backbone in HIV treatment: will it remain relevant?Bone mineral density in people living with HIV: a narrative review of the literature.Efficacy and safety of switching to abacavir/lamivudine (ABC/3TC) plus rilpivirine (RPV) in virologically suppressed HIV-infected patients on HAART.Virological responses to lamivudine or emtricitabine when combined with tenofovir and a protease inhibitor in treatment-naïve HIV-1-infected patients in the Dutch AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort.Switching to darunavir/ritonavir monotherapy vs. triple-therapy on body fat redistribution and bone mass in HIV-infected adults: the Monarch randomized controlled trial.Switch from tenofovir to raltegravir increases low bone mineral density and decreases markers of bone turnover over 48 weeks.Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse EventsImpact of switching from zidovudine/lamivudine to tenofovir/emtricitabine on lipoatrophy: the RECOMB study.Long-term renal safety of tenofovir disoproxil fumarate in vertically HIV-infected children, adolescents and young adults: a 60-month follow-up study.Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care.Prevalence of and risk factors for low bone mineral density in Spanish treated HIV-infected patients.Long-term outcomes of switching to fixed-dose abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC): 3-year results of the BICOMBO study.HIV Reverse Transcriptase InhibitorsChanges in plasma lipidome following initiation of antiretroviral therapy
P2860
Q28533379-03C7E06E-B9AD-4F8F-8F9B-2540980AC912Q28548630-2955A372-0625-485B-B1A8-A5D802E2D096Q28730855-9879E221-CF89-4DEF-BABA-EB35AC3E0706Q28743352-236B5876-41C6-4816-825F-3AE51CA77C7AQ34039680-64BAD019-EEE1-47C5-9ED6-1C506BD1A981Q34478840-270286AB-FE23-4E50-9AD5-9AB51D9E10D7Q34503521-6F075183-BFA7-419B-827B-9E8EF99BD014Q34730407-EA9D848A-124E-4970-9BED-B456696E5A53Q35020217-CA22EAC3-EDA1-4671-A1F6-5210DC33BA7CQ35124959-9F70D63D-C912-4E27-A372-73B3137B4B86Q35186842-8928951D-9697-4EC0-BE7F-A83DF47F2BC5Q35233168-5A4D3E39-C783-4A0B-B2BB-ECEB674D4833Q36048957-AD20A246-48B1-4781-AFFC-C511706E68BDQ36220644-D505DFF2-0BFC-4E05-B2A8-FD7F1B20CB6DQ36426953-28F6D4E4-B520-428A-A8A9-1CBB0DF61ECEQ36553976-0999E35E-E6A1-440F-97AD-EDFC14BCC115Q37077982-1C175C75-7192-4055-9013-A57A6635372DQ37141511-19E152DD-7E7A-4C31-8B52-64E389247B1AQ37296706-2A326715-632E-4D60-A6D3-FE5B97ED6C36Q37696578-B4B364E7-1C91-4188-AA69-E26AE9277CBFQ37756578-415EB630-5B32-4D9F-92D2-D527CFCDCAECQ37828539-BC2D4B6E-139C-45D9-A7D3-82F82F38C10BQ38031028-45345791-D844-42B0-A12E-52680D4F635DQ38215850-D511C247-500A-4DB1-831E-D9DD171ED44BQ38235295-A255A53C-8EFD-45D2-A824-9024B7100FD1Q38879406-EB7C32EF-8FEA-44C3-91B7-E5542CBDBA28Q39533858-0CBBEFDC-F5C3-4653-8693-7F34C716BC8FQ40107245-B94229F7-71A1-4931-B2E0-2FEBD5FA0006Q40790663-00CF561E-FCD1-40C5-A57A-43E7F2AC6CA2Q40806577-455A4E5F-2AFA-4D5F-947C-54DEAA547E65Q42241185-F8698C3E-647F-45A2-928C-2FB29AEDAAE9Q42241391-8E6E2CAD-8ED1-4373-9739-CDCC41478FC7Q42242935-4E9AA0A6-109C-453E-89DF-81A56929DCCCQ42279735-7D09BAFD-8332-4D58-BCD3-861F00E6B873Q51470133-C4E93086-55EA-4B9A-8D3F-B46878A0D832Q51625767-CEF71D94-40A8-40A5-8869-E41A5D2DD274Q54225107-3C3B3D7F-EE68-443D-962D-BDA5A2578D22Q54987366-28E6F53C-7836-4A8E-83EE-E36251CE5790Q56786269-87966145-1EA4-4699-A224-592EFB543DCCQ57167016-8235EC7F-DA5B-415B-89BB-3F6AD2C55AEA
P2860
A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
A simplification trial switchi ...... with virological suppression.
@en
A simplification trial switchi ...... with virological suppression.
@nl
type
label
A simplification trial switchi ...... with virological suppression.
@en
A simplification trial switchi ...... with virological suppression.
@nl
prefLabel
A simplification trial switchi ...... with virological suppression.
@en
A simplification trial switchi ...... with virological suppression.
@nl
P2093
P50
P1476
A simplification trial switchi ...... with virological suppression.
@en
P2093
Alicia González
Ana Cruceta
BICOMBO Study Team
Daniel Podzamczer
David Dalmau
Elena Ferrer
Esperanza Casas
Esteban Martínez
Ferran Segura
Félix Gutiérrez
P304
P356
10.1097/QAI.0B013E3181AA12D5
P407
P577
2009-07-01T00:00:00Z